The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Brigimadlin (BI 907828) is an oral MDM2–p53 antagonist that has shown encouraging antitumor activity in vivo. We present phase Ia results from an open-label, first-in-human, phase Ia/Ib study investigating brigimadlin in patients with advanced solid tumors (NCT03449381). Fifty-four patients received escalating doses of brigimadlin on day 1 of 21-day cycles (D1q3w) or days 1 and 8 of 28-day cycles (D1D8q4w). Based on dose-limiting toxicities during cycle 1, the maximum tolerated dose was selected as 60 mg for D1q3w and 45 mg for D1D8q4w. The most common treatment-related adverse events (TRAE) were nausea (74.1%) and vomiting (51.9%); the most common grade ≥3 TRAEs were thrombocytopenia (25.9%) and neutropenia (24.1%). As evidence of target engagement, time- and dose-dependent increases in growth differentiation factor 15 levels were seen. Preliminary efficacy was encouraging (11.1% overall response and 74.1% disease control rates), particularly in patients with well-differentiated or dedifferentiated liposarcoma (100% and 75% disease control rates, respectively). Significance: We report phase Ia data indicating that the oral MDM2–p53 antagonist brigimadlin has a manageable safety profile and shows encouraging signs of efficacy in patients with solid tumors, particularly those with MDM2-amplified advanced/metastatic well-differentiated or dedifferentiated liposarcoma. Further clinical investigation of brigimadlin is ongoing. See related commentary by Italiano, p. 1765. This article is highlighted in the In This Issue feature, p. 1749
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, brigimadlin has a long half-life (30-60 h in human; 10 h in mice), which supports intermittent dose schedules,11”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a first-in-human phase 1 clinical trial, brigimadlin displayed a favorable pharmacokinetic (PK) profile, with a long plasma elimination half-life and a low apparent volume of distribution.11”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Gamboa, A. C., Gronchi, A., & Cardona, K. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21605 · Cited by 524
Critical aspects of the Bayesian approach to phase I cancer trials
Neuenschwander, B., Branson, M., & Gsponer, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3230 · Cited by 439
Differential sensitivity of liposarcoma subtypes to chemotherapy
Jones, R. L., Fisher, C., Al-Muderis, O., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.023 · Cited by 354
Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review
Thway, K. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.02.006 · Cited by 332
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223 · cited 4×
“However, loss of p53 tumor-suppressor activity can also occur in TP53 wild-type tumors through amplification or overexpression of the key negative regulator of p53, mouse double minute 2 (MDM2) oncoprotein (2, 3).”
BackgroundInfluentialClinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V., Ferraro, R. A., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30496-0 · Cited by 204
Self-citationThe regulation of MDM2 oncogene and its impact on human cancers
Zhao, Y., Yu, H., & Hu, W. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt147 · Cited by 173
PILOTTI, S., TORRE, G. D., LAVARINO, C., PALMA, S. D., SOZZI, G., MINOLETTI, F., RAO, S., PASQUINI, G., AZZARELLI, A., RILKE, F., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199701)181:1<14::aid-path730>3.0.co;2-o · Cited by 149
APOPTOSIS OF HUMAN MONOCYTES/MACROPHAGES INMYCOBACTERIUM TUBERCULOSIS INFECTION
Placido, R., Mancino, G., Amendola, A., Mariani, F., Vendetti, S., Piacentini, M., Sanduzzi, A., Bocchino, M., Zembala, M., & Colizzi, V. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199701)181:1<67::aid-path723>3.0.co;2-z · Cited by 145
Gounder, M. M., Bauer, T. M., Schwartz, G. K., Weise, A. M., LoRusso, P., Kumar, P., Tao, B., Hong, Y., Patel, P., Lu, Y., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01285 · Cited by 99
Self-citationAnalysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
Kato, S., Ross, J. S., Gay, L., Dayyani, F., Roszik, J., Subbiah, V., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00235 · Cited by 78
Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015
Koshiol, J. E., Yu, B., Kabadi, S., Baria, K., & Shroff, R. T. (2022) · BMC Cancer · doi:10.1186/s12885-022-10286-z · Cited by 57
Cornillie, J., Wozniak, A., Li, H., Gebreyohannes, Y. K., Wellens, J., Hompes, D., Debiec-Rychter, M., Sciot, R., & Schöffski, P. (2020) · Clinical and Translational Oncology · doi:10.1007/s12094-019-02158-z · Cited by 56 · cited 3×
“Consistent with previously reported preclinical evidence showing brigimadlin had antitumor activity in patientderived xenografts (12, 13), brigimadlin showed encouraging preliminary efficacy in patients with advanced/ metastatic solid tumors (overall response rate of 11.”
BackgroundResultTakahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., et al. (2021) · Cancer Science · doi:10.1111/cas.14875 · Cited by 50
Self-citationAsano, N., Yoshida, A., Mitani, S., Kobayashi, E., Shiotani, B., Komiyama, M., Fujimoto, H., Chuman, H., Morioka, H., Matsumoto, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14652 · Cited by 47
Kim, Y. J., Sung, M., Yu, D. B., Kim, M., Song, J., Song, K., Jung, K., & Choi, Y. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0263-4 · Cited by 47
Schöffski, P., Lahmar, M., Lucarelli, A., & Maki, R. G. (2023) · Future Oncology · doi:10.2217/fon-2022-1291 · Cited by 44
Self-citationMDM2 Amplification in Intrahepatic Cholangiocarcinomas
Kim, S. J., Akita, M., Sung, Y., Fujikura, K., Lee, J. H., Hwang, S., Yu, E., Otani, K., Hong, S., & Zen, Y. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001006 · Cited by 43
Dembla, V., Somaiah, N., Barata, P. C., Hess, K. R., Fu, S., Jankú, F., Karp, D. D., Naing, A., Piha-Paul, S. A., Subbiah, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26075 · Cited by 43
Italiano, A., Miller, W. H., Blay, J., Gietema, J. A., Bang, Y., Mileshkin, L., Hirte, H. W., Higgins, B., Blotner, S. D., NICHOLS, G. L., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01141-2 · Cited by 41
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma
Schöffski, P. (2022) · Oncology Research and Treatment · doi:10.1159/000524939 · Cited by 39
Bauer, S., Demetri, G. D., Halilovic, E., Dummer, R., Meille, C., Tan, D. S. W., Guerreiro, N., Jullion, A., Ferretti, S., Jeay, S., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01444-4 · Cited by 35
McKean, M. A., Tolcher, A. W., Reeves, J. A., Chmielowski, B., Shaheen, M. F., Beck, J. T., Orloff, M. M., Somaiah, N., Tine, B. A. V., Drabick, J. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.9517 · Cited by 30
Gollner, A., Sini, P., Rudolph, D., Weinstabl, H., Ramharter, J., Weyer-Czernilofsky, U., Golubović, B., Grempler, R., Pitarch, A. P., Sailer, R., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-lb003 · Cited by 6
Research works printed but not linked: 1
- Rudolph, 2018, BI 907828: a novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules [abstract]
Cited by
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 190
The roles of E3 ubiquitin ligases in cancer progression and targeted therapy
Sampson, C., Wang, Q., Otkur, W., Zhao, H., Lu, Y., Liu, X., & Piao, H. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1204 · Cited by 182
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 172
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Bañales, J. M., Rodrigues, P. M., Affò, S., Andersen, J. B., Aspichueta, P., Boulter, L., Bridgewater, J. A., Calvisi, D. F., Cárdenas, A., Cardinale, V., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01153-w · Cited by 133
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Huang, Y., Che, X., Wang, P. W., & Qu, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.001 · Cited by 94
Metadata
- Authors
- LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., & Gounder, M. M.
- Affiliations
- Yale Cancer Center (US)
- National Cancer Centre Japan (JP)
- Florida Cancer Specialists & Research Institute (US)
- Ottawa Hospital (CA)
- Sarah Cannon (US)
- Boehringer Ingelheim (United States) (US)
- Boehringer Ingelheim (Germany) (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Gounder, Mrinal M.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2023-06-03
- Volume
- 13
- Issue
- 8
- Pages
- 1802-1813
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC10401071
- OpenAlex
- W4379259102
- Cited by
- 101
- References
- 29
- Citations by year
- 2026: 21 · 2025: 35 · 2024: 41 · 2023: 4
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim (n/a)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Keywords
- brigimadlin, BI 907828, MDM2-p53 antagonist, p53, advanced solid tumors, metastatic solid tumors, liposarcoma, dedifferentiated liposarcoma, dose-limiting toxicity, maximum tolerated dose, growth differentiation factor 15, target engagement, oral anticancer drugs, treatment efficacy and safety
- MeSH terms
- Antineoplastic Agents, Heterocyclic Compounds, 4 or More Rings, Humans, Liposarcoma, Nausea, Neoplasms, Spiro Compounds, Tumor Suppressor Protein p53, Neoplasms, Second Primary, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.